Technology transfer

Minister Guilbeault leads the Canadian delegation to the UN Climate Change Conference (COP28) to push for ambitious climate action

Retrieved on: 
Monday, November 27, 2023

The Honourable Steven Guilbeault, Minister of Environment and Climate Change, is leading the Canadian delegation to the United Nations Climate Change Conference (COP28) in Dubai, United Arab Emirates, from November 30 to December 12, 2023.

Key Points: 
  • The Honourable Steven Guilbeault, Minister of Environment and Climate Change, is leading the Canadian delegation to the United Nations Climate Change Conference (COP28) in Dubai, United Arab Emirates, from November 30 to December 12, 2023.
  • We will work with partners on a new climate finance goal for 2025 and beyond and identify ways to better leverage private capital for climate solutions.
  • Led by Minister Guilbeault, Canada's delegation includes Catherine Stewart, Ambassador for Climate Change; Michael Bonser, Canada's Chief Climate Negotiator; and Jean-François Tremblay, Deputy Minister of Environment and Climate Change.
  • – The Honourable Steven Guilbeault, Minister of Environment and Climate Change
    COP28 is the 28th Conference of the Parties (COP) to the United Nations Framework Convention on Climate Change (UNFCCC), an annual conference that coordinates international efforts to address climate change.

A Global Leader in Animal Health Selects ValGenesis VLMS to Digitize its Corporate Validation Process

Retrieved on: 
Tuesday, November 21, 2023

SANTA CLARA, Calif., Nov. 21, 2023 /PRNewswire/ -- ValGenesis, Inc., the market leader in enterprise validation lifecycle management systems (VLMS), today announced that a global leader in animal health selected ValGenesis VLMS to digitize its corporate validation process.

Key Points: 
  • SANTA CLARA, Calif., Nov. 21, 2023 /PRNewswire/ -- ValGenesis, Inc., the market leader in enterprise validation lifecycle management systems (VLMS), today announced that a global leader in animal health selected ValGenesis VLMS to digitize its corporate validation process.
  • The company has pharmaceutical, biotechnology, and animal health businesses in more than 150 countries and is working on premium innovations to predict, prevent, and treat diseases in animals.
  • ValGenesis will provide technology transfer services and streamline multiple processes at the company's manufacturing site in Brazil that produces a high-volume commercial product.
  • "We see significant opportunities to modernize processes in the animal health sector with our industry standard digital validation platform which enables transparent processes that are standardized, optimized, and audit-ready."

ST Pharm Presented '100-Day Expedite Strategy', Preparedness and Proactive Measures for Future Pandemic at Korea-CEPI R&D Workshop

Retrieved on: 
Tuesday, November 21, 2023

During the main speaker session, Joo-Sung James Yang, Ph.D., SVP Head of Biotechnology R&D at ST Pharm, addressed the strategy, which aims to develop pandemic vaccines against emerging infectious diseases within 100 days.

Key Points: 
  • During the main speaker session, Joo-Sung James Yang, Ph.D., SVP Head of Biotechnology R&D at ST Pharm, addressed the strategy, which aims to develop pandemic vaccines against emerging infectious diseases within 100 days.
  • ST Pharm highlighted its mRNA platform technologies as a key success factor of '100-Day Expedite Strategy', which are proprietary 5'-capping analogs, marketed as SmartCap®, and LNP drug delivery system, STLNP®.
  • Also, ST PHARM has two different RNA therapeutic biotech companies in the United States, which creates synergistic effects on both CDMO business and new drug/vaccine development.
  • -Vernagen (Atlanta, USA) specialized in the development of mRNA vaccines and antibody-encoding RNA (AER) platform technology for infectious diseases.

Digital Strategies to Accelerate Modern Biopharmaceutical Process Development, Upcoming Webinar Hosted by Xtalks

Retrieved on: 
Monday, November 20, 2023

TORONTO, Nov. 20, 2023 /PRNewswire-PRWeb/ -- In this stimulating webinar, gain insights into overcoming the challenges of biopharmaceutical process development, simplifying digital strategies for cell line development, upstream and downstream processing and analytical operations in modern drug modalities.

Key Points: 
  • In this free webinar, gain insights into implementing strategies in technology transfer and biopharmaceutical process development to drive innovation in modern drug modalities.
  • Attendees will learn about the challenges faced by process development teams and the key digital strategies to improve process development.
  • A new digital approach is required for process teams to thrive in the modern era of biopharmaceutical development.
  • Join this webinar to gain insights into implementing strategies in technology transfer and biopharmaceutical process development to drive innovation in modern drug modalities.

2 Day Virtual Process Validation Training Course: FDA and EU Annex 15 Qualifications and Validation - Enhance your Understanding of the Utilization of Process Validation and Phase 1, 2 and 3

Retrieved on: 
Wednesday, November 15, 2023

DUBLIN, Nov. 15, 2023 /PRNewswire/ -- The "Process Validation Training Course (FDA and EU Annex 15: Qualifications and Validation)" training has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • DUBLIN, Nov. 15, 2023 /PRNewswire/ -- The "Process Validation Training Course (FDA and EU Annex 15: Qualifications and Validation)" training has been added to ResearchAndMarkets.com's offering.
  • This seminar will provide a channel to enhance understanding of the utilization of process validation and Phase 1, 2 and 3, where their guidance blend and where they remain distinct.
  • Common questions asked by the users of Process Validation include:
    How does one integrate these two different concepts (Phase 1, 2, and 3 vs.
  • A Review of EU Annex 15 and its Comparison to FDA's Process Validation Guidance.

GC Genome Enters License Agreement with MP Group

Retrieved on: 
Friday, November 10, 2023

YONGIN, South Korea, Nov. 10, 2023 /PRNewswire/ -- GC Genome Corporation, a leading diagnostics company, today announced that it has entered into a collaboration and exclusive license agreement with MP Group CO., LTD, Bangkok, Thailand to commercialize 'Genome Health' for genetic health checkups. Genome Health, a SNP genotyping service, utilizing next-generation sequencing (NGS) to identify risk alleles associated with major cancer types and general diseases, has been developed by GC Genome. 

Key Points: 
  • YONGIN, South Korea, Nov. 10, 2023 /PRNewswire/ -- GC Genome Corporation, a leading diagnostics company, today announced that it has entered into a collaboration and exclusive license agreement with MP Group CO., LTD, Bangkok, Thailand to commercialize 'Genome Health' for genetic health checkups.
  • We are enthusiastic about the positive impact Genome Health will make in Thailand and beyond," said Dr. Chang-Seok Ki, MD, CEO at GC Genome.
  • Under the terms of the agreement, GC Genome will grant MP Group an exclusive license to commercialize Genome Health within the territory of Thailand.
  • Along with this collaboration, GC Genome and MP Group have inked a Memorandum of Understanding (MoU) to further their partnership in expanding the range of products developed by GC Genome.

Krach Institute for Tech Diplomacy at Purdue Partners with Indiana’s Applied Research Institute to Accelerate Global Tech Security and Innovation in America’s Heartland

Retrieved on: 
Thursday, November 9, 2023

The Krach Institute for Tech Diplomacy at Purdue and the Applied Research Institute (ARI) based in Indiana announced a partnership to accelerate the innovation and adoption of trusted technology to enhance global tech security within the State of Indiana.

Key Points: 
  • The Krach Institute for Tech Diplomacy at Purdue and the Applied Research Institute (ARI) based in Indiana announced a partnership to accelerate the innovation and adoption of trusted technology to enhance global tech security within the State of Indiana.
  • “Our collaboration will bring new opportunities ​to spur innovation, ​extending from Indiana’s Hard Tech Corridor to global capitals worldwide.”
    “We are thrilled to partner with the Krach Institute,” said Dave Roberts, Chief Executive Officer of ARI.
  • The partnership with ARI is the latest in a series of strategic partnerships orchestrated by the Krach Institute for Tech Diplomacy at Purdue.
  • In June, Purdue University and the Krach Institute signed memorandums of understanding with NYCU and NCCU, two research universities in Taiwan, to bolster research and workforce development efforts in Tech Diplomacy and semiconductor-related areas.

Sub Rosa Ventures and Cleveland Electric Labs Awarded National Laboratory Technology Licensing Opportunity for Variational Autoencoder for Network Anomaly Detection

Retrieved on: 
Wednesday, November 8, 2023

TWINSBURG, Ohio, Nov. 8, 2023 /PRNewswire/ -- Sub Rosa Ventures (SRV), Cleveland Electric Labs (CEL), and Idaho National Laboratories (INL) have reached an agreement providing SRV exclusive licensing rights to INL's Patent Application No.

Key Points: 
  • TWINSBURG, Ohio, Nov. 8, 2023 /PRNewswire/ -- Sub Rosa Ventures (SRV), Cleveland Electric Labs (CEL), and Idaho National Laboratories (INL) have reached an agreement providing SRV exclusive licensing rights to INL's Patent Application No.
  • BA-1297 Opportunity: Idaho National Laboratory (INL), managed and operated by Battelle Energy Alliance, LLC (BEA), offering the opportunity for SRV to enter into a license and/or collaborative research agreement to commercialize this variational autoencoder for network anomaly detection.
  • "As a small-business leader, I see daily the importance of bringing these types of game-changing capabilities to market on behalf of the National Labs.
  • This capability goes a long way in addressing the many concerns people have in placing their information sharing eggs in one basket."

Basetwo and Genecis Secure $4.3 Million Project to Revolutionize Life Science Manufacturing with AI-Enabled Digital Twins

Retrieved on: 
Tuesday, November 7, 2023

TORONTO, Nov. 07, 2023 (GLOBE NEWSWIRE) -- Basetwo, in partnership with Genecis, a leading Canadian biotechnology company, is proud to announce $4.3 million in funding from Next Generation Manufacturing Canada (NGen) to spearhead a groundbreaking project that will transform the landscape of life science manufacturing.

Key Points: 
  • The COVID-19 pandemic highlighted several vulnerabilities in local life science manufacturing capabilities across the globe, necessitating a significant increase in domestic production capacity using next-generation technologies.
  • The project also promises to deliver on significant environmental benefits, focusing on optimizing Genecis’ novel manufacturing processes that convert food waste into biodegradable plastics.
  • “We're thrilled to be partnering with Genecis on this project,” said Thouheed Abdul Gaffoor, CEO of Basetwo.
  • For more information about Basetwo, Genecis, and this transformative project, please contact:

EQS-News: Biotest increases EBIT to Euro 125.4 million in the first nine months of 2023

Retrieved on: 
Tuesday, November 7, 2023

This development is due to the higher income taxes in connection with the earnings effect from technology disclosure and development services.

Key Points: 
  • This development is due to the higher income taxes in connection with the earnings effect from technology disclosure and development services.
  • This is equivalent to earnings per ordinary share of € 2.22 compared with € - 0.87 in the same period of the previous year.
  • In September 2023, Biotest also reached an important milestone in the marketing authorisation process for Yimmugo in the USA.
  • This revenue growth is enabled by the commissioning of the Yimmugo® production facility within Biotest Next Level.